AMRI 2Q Revenues: $120.8 million (+35%) 2Q Loss: $21.3 million (earnings were $2.3 million in 2Q15) YTD Revenues: $226.4 million (+32%) YTD Loss: $31.3 million (earnings were $84K YTD15) Comments: Contract revenue was $116.5 million in the quarter, up 37%, driven largely by the addition of Gadea Pharmaceuticals. Recurring royalty revenue was flat at $4.4 million. Research and development expenses were $3.5 million, up from $0.4 million in 2Q15, reflecting increased investment in c...